More than 22 TKIs are currently being utilized in clinical settings or are undergoing advanced clinical trials to target oncogenic drivers of NSCLC, including EGFR, BRAF, MET, ALK fusion rearrangement, and ROS1-fusion rearrangement.3,4 Currently, several FDA-approved first-line therapies exist for patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, which work by competitively blocking ATP binding and subsequent phosphorylation of the EGFR tyrosine kinase domain.5–7. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.